Welcome to our dedicated page for ALLGF news (Ticker: ALLGF), a resource for investors and traders seeking the latest updates and insights on ALLGF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALLGF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALLGF's position in the market.
Alligator Bioscience announced the issuance of U.S. Patent No. 10,774,150 for its bispecific drug candidate, ATOR-1015, which targets CTLA-4 for metastatic cancer treatment. The patent protects this innovation until at least 2036, addressing challenges in immuno-oncology. Safety data from the ongoing Phase I clinical study were presented at ASCO in June 2020, with the study expected to conclude in Q4 2020 and a Phase Ib study planned for 2021.
Alligator Bioscience reported promising biomarker data from a Phase I study of mitazalimab, a CD40 antibody targeting pancreatic cancer. Results show significant gene upregulation, including PD-L1, which suggests the potential for enhanced tumor response to PD-1 therapy. The data supports a Phase II trial (OPTIMIZE-1) planned for December 2020, assessing mitazalimab in combination with chemotherapy. The study's findings were presented at the PEGS summit, indicating a stronger confidence in mitazalimab's efficacy and market potential.
Alligator Bioscience announced interim safety data for its drug candidate ATOR-1017, a 4-1BB antibody for treating metastasized cancer. The Phase I study showed a promising safety profile with few mild or moderate adverse events. The Data Review Committee has approved a higher dose of 100 mg for dosing. CEO Per Norlén expressed optimism about the drug's potential, highlighting its tolerability compared to typical 4-1BB therapies. A public R&D update is scheduled for Aug 27, 2020, to discuss further developments.
Alligator Bioscience (Nasdaq Stockholm: ATORX) will provide updates on its clinical drug candidates mitazalimab, ATOR-1015, and ATOR-1017 during a virtual R&D Day on August 27, 2020. Mitazalimab, targeting metastatic pancreatic cancer, will submit a Phase II clinical trial application by December 2020. Early signs of efficacy and safety were noted in prior studies. ATOR-1015 is advancing to Phase Ib studies for malignant melanoma with encouraging tolerability data. ATOR-1017 is in a Phase I study to activate T-cells for cancer treatment. Further details will be shared at the R&D Day.
